Short Interest in Apollomics, Inc. (NASDAQ:APLM) Grows By 637.6%

Apollomics, Inc. (NASDAQ:APLM) saw a significant growth in short interest in the month of July. As of July 31st, there was short interest totalling 394,600 shares, a growth of 637.6% from the July 15th total of 53,500 shares. Approximately 0.7% of the shares of the company are sold short. Based on an average daily volume of 1,090,000 shares, the days-to-cover ratio is currently 0.4 days.

Analyst Ratings Changes

Separately, HC Wainwright cut their price target on Apollomics from $5.00 to $2.00 and set a “buy” rating for the company in a research note on Wednesday, May 8th.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Apollomics stock. Powell Investment Advisors LLC purchased a new position in shares of Apollomics, Inc. (NASDAQ:APLM) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 130,297 shares of the company’s stock, valued at approximately $98,000. Powell Investment Advisors LLC owned approximately 0.15% of Apollomics as of its most recent filing with the Securities and Exchange Commission (SEC). 19.13% of the stock is owned by hedge funds and other institutional investors.

Apollomics Stock Performance

Shares of APLM traded down $0.01 during trading hours on Wednesday, hitting $0.13. 4,175,582 shares of the company were exchanged, compared to its average volume of 1,629,893. The firm’s fifty day moving average is $0.20 and its 200 day moving average is $0.43. Apollomics has a fifty-two week low of $0.12 and a fifty-two week high of $5.28.

Apollomics Company Profile

Apollomics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain.